XXXiaoya Xu

Xiaoya Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaoya Xu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Dadong Zhang

    Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China

    2 shared publications
  • Wei Zhang

    Department of Clinical and Translational Research 3D Medicines Inc. Shanghai 201114 China

    2 shared publications
  • Baoning Nian

    3D Med Inc, Dept Clin & Translat Med, 158 Xinjunhuan Rd,Pujiang Hi Tech Pk, Shanghai 201114, Peoples R China

    1 shared publication
  • Chao Yang

    Taizhou Hosp Zhejiang Prov, Blood Purificat Ctr, Taizhou, Peoples R China

    1 shared publication
  • Chenhui Zhao

    Department of Oncology The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital) Nanjing 210029 China

    1 shared publication
  • Fabiao Zhang

    Key Laboratory of Minimally Invasive Techniques and Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Department of Hepatobiliary Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, China

    1 shared publication

Latest Publications

  • Open Access

    Integrative Multi‐Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer

    by Jianchao Wang, Wenfang Zhang, Jiyang Zhang, Chenhui Zhao, Wei Zhang, Menghan Fang, Fangfang Chen, Zhida Wu, Xiaoya Xu, Ziqing Yu, et al.

    Current understanding of immune characteristics in gastric cancer remains limited for guiding clinical practice, particularly immunotherapy. This study aims to elucidate the multidimensional landscape of tumor microenvironment in gastric cancer, identify predictive biomarkers potentially associated with favorable immunotherapy response, and propose a precision stratification framework to inform therapeutic strategies. This study introduces a novel immune classification system tumor immune microenvironment (TIME)‐inflamed, TIME‐desert, and TIME‐excluded), and characterize the cellular and molecular characteristics of each subtype. TIME‐inflamed tumors exhibit significantly higher infiltration of immune cells in tumor regions, as well as increased expression of inflamed‐genes. TIME‐desert tumors display minimal immune cell infiltration and feature abnormal microvasculature. TIME‐excluded subtype is defined by immune cell accumulation outside the tumor with ineffective intratumoral infiltration, prominent fibroblast activity, and collagen deposition. Application of this immune classification system to stratify gastric cancer within the SPACE cohort successfully demonstrates potential for predicting favorable outcomes of a subset of “cold tumor” patients upon receiving combined immunotherapy and chemotherapy. The findings contribute to advancing the classification of gastric cancer from traditional histopathological subtyping to functional immunological subtyping, providing a valuable scientific foundation for precise patient stratification and the development of individualized immunotherapy strategies in clinical practice.


  • Open Access

    Optimal preservation condition for the extraction of cell-free DNA from bile of patients with biliary tract cancer

    by Jian Yang, Teng Zhao, Baoning Nian, Chao Yang, Yu Zhu, Yongfu Xu, Xiaoya Xu, Sheng Chen, Zhikuan Li, Wei Zhang, et al.

    Background: Patients with biliary tract cancer (BTC) often have dismal outcomes due to the poor performance of traditional methods for early diagnosis. Recently, bile cell-free DNA (cfDNA) has been reported as a potential liquid biopsy material for BTC diagnosis. However, bile is a complex alkaline aqueous medium, and the proper storage conditions for bile remain to be explored. The aim of this study is to explore the effects of storing bile under various conditions on the stability of bile cfDNA and to determine the optimal conditions, thereby establishing a foundation for the subsequent application of bile cfDNA in liquid biopsy for early diagnostic and prognosis monitoring of patients with malignant BTC. Methods: We evaluated the storage temperature and storage time for the preservation of bile samples. Bile samples were collected in cfDNA tubes with protectant covered inside or regular tubes without, and the stability of bile cfDNA was analyzed during 10 days at room temperature (RT) or after 2 months of storage at low temperatures. Results: Bile cfDNA remained stable for bile samples being collected with cfDNA tubes and stored for 10 days at RT, while degraded with time for the case with regular tubes. When bile samples were collected with cfDNA tubes and stored for 2 months at 4 ℃, bile cfDNA remained stable, however, if collected with regular tubes, bile cfDNA exhibited a slight loss of integrity. No significant difference was observed for 2 months storage at −20 or −80 ℃. Conclusions: Our findings suggested that for bile cfDNA research, bile samples should be collected with cfDNA tubes and it can be transported for short-term shipment at RT, and could be stored at 4 ℃ with cfDNA tubes, or frozen at −20 ℃ with regular tubes.